The Endometriosis market growth is driven by factors like increase in the prevalence of Endometriosis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Endometriosis market report also offers comprehensive insights into the Endometriosis market size, share, Endometriosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Endometriosis market size growth forward.
Some of the key highlights from the Endometriosis Market Insights Report:
Strategise your business goals by understanding market dynamics @ Endometriosis Market Landscape
Endometriosis Overview
Endometriosis is a condition characterized by the presence of endometrial tissue outside the uterus, leading to recurring bleeding within these abnormal tissue growths. This happens because the ectopic endometrial tissue is responsive to hormonal changes, resulting in the formation of fibrous tissue. The disease primarily affects adolescents and women of reproductive age, and it is commonly associated with chronic pelvic pain and infertility. The most frequent sites where endometriosis occurs are the ovaries, pelvic peritoneum (the membrane lining the pelvic cavity), uterosacral ligaments, and torus uterus. However, atypical locations can also be observed, including the cervix, round ligaments, ureters, and nerves. In rare cases, endometriosis implants can even be found outside the pelvic area, such as in the upper abdomen, subphrenic fold, or abdominal wall.
Diagnosing endometriosis is often delayed, typically taking an average of 4 to 11 years from the onset of symptoms. This delay occurs due to the absence of a definitive test or biomarker for the disease and the overlap of symptoms with other gastrointestinal or gynecological conditions. The symptoms experienced by patients, including pain and discomfort during menstruation, may be mistakenly considered as normal physiological responses. To accurately diagnose endometriosis, a physician should gather a detailed medical history and perform a gynecological physical examination. The gold standard for diagnosis is laparoscopy, which involves exploring the abdominal cavity and obtaining a tissue sample for histological analysis. However, ultrasound and MRI can be used to detect ovarian endometriomas (cysts) and deep nodular forms of the disease.
The management of endometriosis requires a multidisciplinary approach. Treatment typically involves surgical intervention to diagnose and remove endometrial lesions, hormonal therapy to suppress the disease and prevent its recurrence and progression, pain management strategies offered by specialized pain centers, and pelvic therapy. Both surgical and medical treatments are equally effective in managing symptomatic endometriosis. Despite available pain treatments, recurrence of endometriosis is not uncommon. The choice of medical treatment depends on factors such as side effects, cost, and individual preferences. Initially, non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose combined oral contraceptive pills (COCPs) containing ethyl estradiol and progestins are commonly prescribed. If NSAIDs do not provide relief within three months, the next line of treatment options includes progestins (administered orally, via injection, or intra-uterine), androgens, and gonadotropin-releasing hormone agonists (GnRH) which effectively reduce moderate to severe pain associated with endometriosis.
Do you know the treatment paradigms for different countries? Download our Endometriosis Market Sample Report
Endometriosis Epidemiology Insights
Endometriosis Epidemiology Segmentation
DelveInsight’s Endometriosis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Endometriosis historical patient pools and forecasted Endometriosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Endometriosis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Endometriosis Epidemiological Insights
Recent Advances in the Treatment of Endometriosis
Endometriosis Treatment Market
The management of endometriosis requires a multidisciplinary approach with surgical diagnosis and debulking of disease load, hormonal treatment to suppress and delay recurrence and progression of disease, pain management strategies best provided by a pain center clinic that develops individualized care plans, and pelvic therapy. Symptomatic endometriosis is typically treated by surgical or medical treatment, both equally effective. Despite the available associated pain treatments, endometriosis recurrence is not uncommon. Medical treatment choices are based on side effect profile, cost, and personal preference. Non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose combined oral contraceptive pills (COCPs) such as ethyl estradiol and progestins are the first choice drugs. If patients do not respond to NSAIDs in 3 months, the second line of treatments is used, which includes progestins (oral, injectable, and intra-uterine), androgens, and gonadotropin-releasing hormone agonists (GnRH), which reduce moderate-to-severe pain of endometriosis.
The Endometriosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Endometriosis market trends by analyzing the impact of current Endometriosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
According to DelveInsight, the Endometriosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Endometriosis Therapy Assessment
Linzagolix: ObsEva
ObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries. Through previously reported results from linzagolix and sophisticated pharmacological modelling, it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression. In 2015, ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co., which had completed several Phase 2a clinical trials in Japan.Currently, the drug is being evaluated in Phase III clinical trial evaluation for the treatment of Endometriosis.
Relugolix: Myovant Sciences
Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the treatment of endometriosis and for the prevention of pregnancy. Phase III clinical program for endometriosis consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis. In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase III SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.
Endometriosis Key Companies
For more information, visit Endometriosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Endometriosis Market Report:
Key Questions Answered in the Endometriosis Market Report 2032:
Table of Contents:
1 Endometriosis Market Key Comprehensive Insights
2 Endometriosis Market Report Introduction
3 Competitive Intelligence Analysis for Endometriosis
4 Endometriosis Market Analysis Overview at a Glance
5 Executive Summary of Endometriosis
6 Endometriosis Epidemiology and Market Methodology
7 Endometriosis Epidemiology and Patient Population
8 Endometriosis Patient Journey
9 Endometriosis Treatment Algorithm, Endometriosis Current Treatment, and Medical Practices
10 Key Endpoints in Endometriosis Clinical Trials
11 Endometriosis Marketed Therapies
12 Endometriosis Emerging Therapies
13 Endometriosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Endometriosis
16 Endometriosis Market Key Opinion Leaders Reviews
18 Endometriosis Market Drivers
19 Endometriosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Endometriosis Epidemiology 2032
DelveInsight’s “Endometriosis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometriosis Pipeline 2023
“Endometriosis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Endometriosis market. A detailed picture of the Endometriosis pipeline landscape is provided, which includes the disease overview and Endometriosis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
